Millions of Medicare Part D enrollees who depend on Ozempic, Wegovy, and other high-cost chronic-disease drugs are set to pay less starting January 1, 2027, after the Centers for Medicare and Medicaid Services finalized Maximum Fair Prices for 15 medications. About 5.3 million beneficiaries used one of the 15 selected drugs in 2024, and total gross spending on those medicines reached roughly $42.5 billion that year. The projected $685 million in savings for seniors reflects the scale of price reductions that federal negotiations are expected to deliver across these products.
Why the 2027 Medicare price cuts hit seniors’ budgets directly
CMS finalized the Maximum Fair Prices, or MFPs, for 15 Part D drugs as part of the Medicare Drug Price Negotiation Program. Those prices take effect on January 1, 2027, creating a hard ceiling on what Medicare pays for each product. For enrollees on fixed incomes who currently face steep copays or coinsurance on brand-name semaglutide prescriptions, the lower negotiated prices translate into smaller out-of-pocket costs at the pharmacy counter.
The three Novo Nordisk semaglutide products, Ozempic, Rybelsus, and Wegovy, were among the 15 additional drugs HHS selected for negotiation. Negotiations took place during 2025, and the resulting prices apply in 2027. Because semaglutide products rank among the highest-spend medicines in Part D, even a modest percentage reduction generates large aggregate savings spread across millions of prescriptions.
A related question is whether the published MFPs will ripple beyond Medicare. Under federal Medicaid best-price rules, manufacturers must offer state Medicaid programs the lowest price available to any purchaser. If the negotiated Medicare price falls well below current commercial rates, drugmakers face pressure to realign retail pricing or risk triggering even deeper Medicaid rebate obligations. That dynamic could push average cash-pay prices for semaglutide lower at retail pharmacies within roughly 18 months of the 2027 effective date, though the exact magnitude remains uncertain because CMS has not published a formal spillover analysis.
CMS data and timelines behind the $685 million projection
The savings figure is anchored to CMS data showing that approximately 5.3 million Part D enrollees filled prescriptions for the 15 drugs in 2024, generating about $42.5 billion in total gross spending. The MFPs set a new price for a 30-day equivalent supply of each drug, and the difference between that ceiling and the prior net cost produces the projected savings. CMS has posted the official negotiated-price files, including NDC-level per-unit details, on its selected drugs page for public review.
The negotiation program itself has moved in stages. HHS selected the first 10 drugs for price negotiation on August 29, 2023. The second round added 15 more, including the semaglutide trio, with negotiations conducted through 2025 and prices locked for implementation in 2027. CMS describes this multi-year process, along with the statutory timelines and comment periods, in its program guidance for plans, manufacturers, and other stakeholders.
Under the law, once a drug is selected, CMS develops an initial offer based on factors such as clinical benefit, unmet medical need, and existing therapeutic alternatives. Manufacturers can submit counteroffers, and the parties move through several rounds of discussion before CMS issues a final MFP. Those confidential negotiations culminate in a public list of ceiling prices that Part D plans must honor beginning with the 2027 plan year.
How the new prices could change plan design
While the MFPs directly cap what Medicare and its contracted plans pay, they also reshape how insurers design their formularies. Lower net prices make it easier for Part D plans to place high-cost drugs like Ozempic and Wegovy on preferred tiers with reduced coinsurance. Plans may respond by cutting monthly premiums more aggressively or by shifting savings into lower deductibles and cost-sharing for chronic-disease therapies.
For beneficiaries, the impact will vary by plan and drug. Patients who currently hit the catastrophic coverage threshold because of expensive diabetes or obesity medications may see fewer months in which they owe high coinsurance. Others who have avoided starting semaglutide due to cost may find that a negotiated MFP brings their share into a more affordable range, especially once the 2027 Part D benefit redesign and out-of-pocket caps interact with the new price ceilings.
What patients and prescribers should watch next
Between now and 2027, the key milestones will be how Part D sponsors incorporate the MFPs into their annual bids and how manufacturers adjust broader pricing strategies. CMS will continue to update technical files and operational guidance so plans can program the new ceilings into their systems. Advocates for seniors are likely to scrutinize whether plans pass through the full benefit of negotiated prices or offset savings with higher premiums elsewhere in the benefit.
Clinicians prescribing semaglutide for diabetes or obesity will need to monitor evolving formulary rules, prior-authorization requirements, and step-therapy policies as plans respond to the new economics. Patients, meanwhile, can expect more detailed plan materials in the 2026 and 2027 open-enrollment seasons explaining how negotiated prices affect their expected out-of-pocket costs.
What is clear from CMS’s projections is that the first wave of negotiated MFPs is large enough to matter for millions of older adults managing chronic conditions. Whether the ripple effects extend meaningfully into commercial and cash markets will depend on how manufacturers and payers react once the 2027 prices are in force, but for Medicare beneficiaries, the path to lower pharmacy bills is now formally set.
